Researchers to develop bioinks using unique hydrogel
(LOS ANGELES)– The Terasaki Institute for Biomedical Innovation (TIBI) has formally signed a collaborative agreement with Tetratherix™, a company which produces Tetramatrix, a synthetic injectable hydrogel currently being clinically tested in a variety of biomedical applications.
Tetramatrix exhibits superior injectability, responsiveness to body temperature and tunable properties. It is also highly biocompatible and biodegradable and because it is purely synthetic, it is not subject to the regulatory and manufacturing restrictions of animal or human-derived products. The unique and advantageous features of Tetramatrix offers the potential for further development into biocompatible, adhesive bioinks for deep tissue applications.